Navigation Links
BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
Date:1/6/2011

LYNBROOK, N.Y., Jan. 6, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company" or "BioSpecifics"), a biopharmaceutical company developing first in class collagenase-based products, today announced promising results from its study Chien-802 showing dramatic reductions in canine lipoma following injections with purified injectable collagenase. These results build upon an earlier dose escalation study from which the Company selected the dose for Chien-802. The Company also announced today the initiation of a larger clinical trial, Chien-803, for the same indication.  

Canine lipomas represent a potentially large market with the current cost of treating canine lipomas on an annual basis of approximately $635 million in the United States. BioSpecifics previously announced results from a human clinical trial that demonstrated an average of 93% post treatment decrease in the size of a lipoma with a single collagenase injection in human lipoma.

"We are excited about the promising study results in lipoma and are enthusiastic about the use of injectable collagenase both in humans and in canines," commented Thomas L. Wegman, President of BioSpecifics. "BioSpecifics is deeply committed to conducting additional clinical trials that demonstrate the potential of injectable collagenase in a range of indications. We believe that new indications have the potential to have a major impact on the market for injectable collagenase."  

About Chien-801 and Chien-802 Clinical Trials Chien-801 was a pilot study conducted for the purpose of evaluating the use of purified collagenase for the non-surgical treatment of lipoma in six dogs. The study evaluated the appropriate dosage and frequency of injections necessary to significantly reduce the size of the lipoma. The dose administered ranged from 0.012 to 0.021 mg/ cm2 which was approximately 1/2 to
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
2. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
3. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
4. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
6. BioSpecifics Technologies Corp. Stock Trading Halted Today
7. BioSpecifics Technologies Corp. To Present at BioCentury NewsMakers in the Biotech Industry Conference
8. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
9. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
11. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
(Date:7/24/2014)... Livermore, California (PRWEB) July 24, 2014 ... due to advances in modeling lithium-ion battery storage ... could benefit from a theoretical model created at ... Rice University that predicts how carbon components ... for energy storage emphasizes the urgent need for ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... 2014 Deep Research Report on Global ... and in-depth research report on Potassium Sulphate ... information, including its definition, classification, application, and industry ... the international market analysis, including China’s domestic market ... environment & economic situation analysis, the influence of ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... 2, 2011 Myriant Technologies, Inc. (Myriant), a ... chemicals, announces the addition of J. Brian Ferguson ... Ferguson, 56, is the former CEO and Chairman ... engaged in the manufacture and sale of a ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), ... vaccines against cancers and infectious diseases, announced today that ... DNA vaccine for foot-and-mouth disease administered by Inovio,s proprietary ... Dr. Niranjan Y. Sardesai, Inovio,s Sr. VP of Research ...
... sharp object has put Canadian researchers at the National Institute ... Book of World Records. Only one atom at its ... sharpest man-made object. It is made of Tungsten and ... being evaluated for its commercial potential., "We did not start ...
Cached Biology Technology:Myriant Technologies, Inc. Announces J. Brian Ferguson to Join Advisory Board 2Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 2Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 3Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 4Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 5Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 6
(Date:7/24/2014)... Mass. (July 24, 2014) For years, researchers and ... forming nearly any cell type in the bodycould provide ... treat them. Yet progress has been hampered by the ... studies to their human counterparts, in part because human ... mouse cells. , Now Thorold Theunissen, Benjamin Powell, and ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... available in German . ... and respond to threats to health, and to provide ... of the mechanism underlying immunologic memory, however, has remained ... to support the hypothesis that the persistence of immune ... stem-cell-like potential. Until now, there was no conclusive evidence, ...
Breaking Biology News(10 mins):Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3
... the third most common family of epidermal growth factor ... Little is known about cancers harboring these mutations aside ... inhibitors, impairing the development of effective targeted therapies. A ... the International Association for the Study of Lung Cancer,s ...
... visualizing Earth science data from a NASA and U.S. Geological ... the ability to tease out the small events that can ... computer program is able to find patterns previously buried within ... led to seeing for the first time in satellite imagery ...
... 2013 A new study has found that tamoxifen, ... features in a mouse model of Duchenne muscular dystrophy ... long-term improvement of the symptoms in boys with DMD, ... muscle wasting, respiratory and cardiac impairments, paralysis, and premature ...
Cached Biology News:Landsat senses a disturbance in the forest 2Landsat senses a disturbance in the forest 3Landsat senses a disturbance in the forest 4Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy 2
... Reticulocyte Lysate contains the cellular components necessary ... initiation, elongation and termination factors) but has ... Lysate is used primarily for the isolation ... source of endogenous globin mRNA. Untreated Lysate ...
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
Form: Concentrated Applications: ELISA...
Biology Products: